Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations
• Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Santini, Valeria [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: N - Li, Danyang ELSEVIER, 2019, clinical and laboratory studies, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:38 ; year:2014 ; number:12 ; pages:1381-1391 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.leukres.2014.09.008 |
|---|
| Katalog-ID: |
ELV017314062 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV017314062 | ||
| 003 | DE-627 | ||
| 005 | 20230623134228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.leukres.2014.09.008 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014003000025.pica |
| 035 | |a (DE-627)ELV017314062 | ||
| 035 | |a (ELSEVIER)S0145-2126(14)00285-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 333.7 |a 610 |q VZ |
| 084 | |a 43.12 |2 bkl | ||
| 084 | |a 43.13 |2 bkl | ||
| 084 | |a 44.13 |2 bkl | ||
| 100 | 1 | |a Santini, Valeria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations |
| 264 | 1 | |c 2014 | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine. | ||
| 650 | 7 | |a Refractory |2 Elsevier | |
| 650 | 7 | |a Relapse |2 Elsevier | |
| 650 | 7 | |a Azacitidine |2 Elsevier | |
| 650 | 7 | |a Hypomethylating agents |2 Elsevier | |
| 650 | 7 | |a MDS |2 Elsevier | |
| 650 | 7 | |a Consensus |2 Elsevier | |
| 650 | 7 | |a Salvage therapy |2 Elsevier | |
| 700 | 1 | |a Prebet, Thomas |4 oth | |
| 700 | 1 | |a Fenaux, Pierre |4 oth | |
| 700 | 1 | |a Gattermann, Norbert |4 oth | |
| 700 | 1 | |a Nilsson, Lars |4 oth | |
| 700 | 1 | |a Pfeilstöcker, Michael |4 oth | |
| 700 | 1 | |a Vyas, Paresh |4 oth | |
| 700 | 1 | |a List, Alan F. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Li, Danyang ELSEVIER |t N |d 2019 |d clinical and laboratory studies |g Amsterdam [u.a.] |w (DE-627)ELV002185202 |
| 773 | 1 | 8 | |g volume:38 |g year:2014 |g number:12 |g pages:1381-1391 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.leukres.2014.09.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-GGO | ||
| 936 | b | k | |a 43.12 |j Umweltchemie |q VZ |
| 936 | b | k | |a 43.13 |j Umwelttoxikologie |q VZ |
| 936 | b | k | |a 44.13 |j Medizinische Ökologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 38 |j 2014 |e 12 |h 1381-1391 |g 11 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
v s vs |
|---|---|
| matchkey_str |
santinivaleriaprebetthomasfenauxpierrega:2014----:iiiigikfyoehltnaetalriptetwthgersmsnpat |
| hierarchy_sort_str |
2014 |
| bklnumber |
43.12 43.13 44.13 |
| publishDate |
2014 |
| allfields |
10.1016/j.leukres.2014.09.008 doi GBVA2014003000025.pica (DE-627)ELV017314062 (ELSEVIER)S0145-2126(14)00285-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Santini, Valeria verfasserin aut Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations 2014 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine. Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy Elsevier Prebet, Thomas oth Fenaux, Pierre oth Gattermann, Norbert oth Nilsson, Lars oth Pfeilstöcker, Michael oth Vyas, Paresh oth List, Alan F. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:12 pages:1381-1391 extent:11 https://doi.org/10.1016/j.leukres.2014.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 12 1381-1391 11 045F 610 |
| spelling |
10.1016/j.leukres.2014.09.008 doi GBVA2014003000025.pica (DE-627)ELV017314062 (ELSEVIER)S0145-2126(14)00285-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Santini, Valeria verfasserin aut Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations 2014 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine. Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy Elsevier Prebet, Thomas oth Fenaux, Pierre oth Gattermann, Norbert oth Nilsson, Lars oth Pfeilstöcker, Michael oth Vyas, Paresh oth List, Alan F. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:12 pages:1381-1391 extent:11 https://doi.org/10.1016/j.leukres.2014.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 12 1381-1391 11 045F 610 |
| allfields_unstemmed |
10.1016/j.leukres.2014.09.008 doi GBVA2014003000025.pica (DE-627)ELV017314062 (ELSEVIER)S0145-2126(14)00285-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Santini, Valeria verfasserin aut Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations 2014 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine. Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy Elsevier Prebet, Thomas oth Fenaux, Pierre oth Gattermann, Norbert oth Nilsson, Lars oth Pfeilstöcker, Michael oth Vyas, Paresh oth List, Alan F. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:12 pages:1381-1391 extent:11 https://doi.org/10.1016/j.leukres.2014.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 12 1381-1391 11 045F 610 |
| allfieldsGer |
10.1016/j.leukres.2014.09.008 doi GBVA2014003000025.pica (DE-627)ELV017314062 (ELSEVIER)S0145-2126(14)00285-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Santini, Valeria verfasserin aut Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations 2014 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine. Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy Elsevier Prebet, Thomas oth Fenaux, Pierre oth Gattermann, Norbert oth Nilsson, Lars oth Pfeilstöcker, Michael oth Vyas, Paresh oth List, Alan F. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:12 pages:1381-1391 extent:11 https://doi.org/10.1016/j.leukres.2014.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 12 1381-1391 11 045F 610 |
| allfieldsSound |
10.1016/j.leukres.2014.09.008 doi GBVA2014003000025.pica (DE-627)ELV017314062 (ELSEVIER)S0145-2126(14)00285-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Santini, Valeria verfasserin aut Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations 2014 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine. Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy Elsevier Prebet, Thomas oth Fenaux, Pierre oth Gattermann, Norbert oth Nilsson, Lars oth Pfeilstöcker, Michael oth Vyas, Paresh oth List, Alan F. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:12 pages:1381-1391 extent:11 https://doi.org/10.1016/j.leukres.2014.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 12 1381-1391 11 045F 610 |
| language |
English |
| source |
Enthalten in N Amsterdam [u.a.] volume:38 year:2014 number:12 pages:1381-1391 extent:11 |
| sourceStr |
Enthalten in N Amsterdam [u.a.] volume:38 year:2014 number:12 pages:1381-1391 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Umweltchemie Umwelttoxikologie Medizinische Ökologie |
| institution |
findex.gbv.de |
| topic_facet |
Refractory Relapse Azacitidine Hypomethylating agents MDS Consensus Salvage therapy |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
N |
| authorswithroles_txt_mv |
Santini, Valeria @@aut@@ Prebet, Thomas @@oth@@ Fenaux, Pierre @@oth@@ Gattermann, Norbert @@oth@@ Nilsson, Lars @@oth@@ Pfeilstöcker, Michael @@oth@@ Vyas, Paresh @@oth@@ List, Alan F. @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV002185202 |
| dewey-sort |
3610 |
| id |
ELV017314062 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017314062</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623134228.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.leukres.2014.09.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014003000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017314062</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0145-2126(14)00285-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Santini, Valeria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Refractory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Relapse</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Azacitidine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hypomethylating agents</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MDS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Consensus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Salvage therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prebet, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fenaux, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gattermann, Norbert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nilsson, Lars</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pfeilstöcker, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vyas, Paresh</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">List, Alan F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Li, Danyang ELSEVIER</subfield><subfield code="t">N</subfield><subfield code="d">2019</subfield><subfield code="d">clinical and laboratory studies</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002185202</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:1381-1391</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.leukres.2014.09.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.13</subfield><subfield code="j">Umwelttoxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2014</subfield><subfield code="e">12</subfield><subfield code="h">1381-1391</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Santini, Valeria |
| spellingShingle |
Santini, Valeria ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations |
| authorStr |
Santini, Valeria |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV002185202 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 333 - Economics of land & energy |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy Elsevier |
| topic |
ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy |
| topic_unstemmed |
ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy |
| topic_browse |
ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Refractory Elsevier Relapse Elsevier Azacitidine Elsevier Hypomethylating agents Elsevier MDS Elsevier Consensus Elsevier Salvage therapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t p tp p f pf n g ng l n ln m p mp p v pv a f l af afl |
| hierarchy_parent_title |
N |
| hierarchy_parent_id |
ELV002185202 |
| dewey-tens |
610 - Medicine & health 330 - Economics |
| hierarchy_top_title |
N |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV002185202 |
| title |
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations |
| ctrlnum |
(DE-627)ELV017314062 (ELSEVIER)S0145-2126(14)00285-9 |
| title_full |
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations |
| author_sort |
Santini, Valeria |
| journal |
N |
| journalStr |
N |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
1381 |
| author_browse |
Santini, Valeria |
| container_volume |
38 |
| physical |
11 |
| class |
610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Santini, Valeria |
| doi_str_mv |
10.1016/j.leukres.2014.09.008 |
| dewey-full |
610 333.7 |
| title_sort |
minimizing risk of hypomethylating agent failure in patients with higher-risk mds and practical management recommendations |
| title_auth |
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations |
| abstract |
• Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine. |
| abstractGer |
• Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine. |
| abstract_unstemmed |
• Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO |
| container_issue |
12 |
| title_short |
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations |
| url |
https://doi.org/10.1016/j.leukres.2014.09.008 |
| remote_bool |
true |
| author2 |
Prebet, Thomas Fenaux, Pierre Gattermann, Norbert Nilsson, Lars Pfeilstöcker, Michael Vyas, Paresh List, Alan F. |
| author2Str |
Prebet, Thomas Fenaux, Pierre Gattermann, Norbert Nilsson, Lars Pfeilstöcker, Michael Vyas, Paresh List, Alan F. |
| ppnlink |
ELV002185202 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.leukres.2014.09.008 |
| up_date |
2024-07-06T21:40:29.479Z |
| _version_ |
1803867420864020480 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017314062</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623134228.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.leukres.2014.09.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014003000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017314062</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0145-2126(14)00285-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Santini, Valeria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Refractory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Relapse</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Azacitidine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hypomethylating agents</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MDS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Consensus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Salvage therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prebet, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fenaux, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gattermann, Norbert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nilsson, Lars</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pfeilstöcker, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vyas, Paresh</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">List, Alan F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Li, Danyang ELSEVIER</subfield><subfield code="t">N</subfield><subfield code="d">2019</subfield><subfield code="d">clinical and laboratory studies</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002185202</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:1381-1391</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.leukres.2014.09.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.13</subfield><subfield code="j">Umwelttoxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2014</subfield><subfield code="e">12</subfield><subfield code="h">1381-1391</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.402231 |